Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC).

The 32-week study will enroll 15–20 adults aged 18–80 with Parkinson's-related hyposmia, featuring a 24-week treatment period of twice-daily CYR-064 nasal sprays.

In addition to failing to separate itself on the primary end point, EVT + best medical care was associated with higher rates of serious adverse events (33.9% vs 25.7%) and mortality (13.3% vs 8.4%) compared to best medical care alone.

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Véronique Miron, PhD. [LISTEN TIME: 17 minutes]

Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.

The trial evaluates safety, remyelination, and functional outcomes, including changes in low contrast letter acuity, MRI myelination measures, and MS disease activity.

Compared with Alzheimer disease, those with behavioral variant FTD demonstrated increased light sleep (N1%) and reduced deep sleep (N3%), alongside altered sleep dynamics, such as higher transitions between N1 sleep and wake states.

Over a 52-week treatment period, patients who continued on bexicaserin and those who switched from placebo demonstrated notable decreases in motor seizures, further supporting the agent’s development.

In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.

SPN-830 is a wearable subcutaneous infusion device designed to deliver continuous treatment throughout the waking day, ensuring more consistent control of OFF time.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

UCB’s rozanolixizumab introduces two new self-administration methods, empowering patients with generalized myasthenia gravis (gMG) to manage their treatment with greater independence and control.

Jacqueline A. French, MD, a professor of neurology at the NYU Grossman School of Medicine, provided clinical perspectives on her experiences and career growth in neurology amid National Women Physicians Day.

Jean Hubble, MD, a retired movement disorder specialist and consultant to the PMD Alliance, shares her reflections on National Women Physicians Day, the unique contributions of women in neurology, and the pathways to fostering future leaders in movement disorders care.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Pompe disease.

Cognitive behavioral therapy for insomnia, a multicomponent psychotherapy, consists of sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.

Suzetrigine, a selective inhibitor of the NaV1.8 sodium channel, offers an alternative opioid treatment option for patients to treat moderate to severe pain without risk of addiction.

The initial cohort of the EPISOD1 trial demonstrated no significant safety concerns for AMT-162, enabling progression to the next dose-escalation phase.

Significant improvements were observed in depression and patient satisfaction with fascia exercises compared to conventional physiotherapy.

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

The submission was based on promising data from a phase 3 and phase 2 study, where treatment with apitegromab led to significant improvements in motor function among patients with SMA on SMN-targeted treatments.

The neurointensivist and assistant professor of neurology at Boston Medical Center gave insight on a 2024 paper establishing entrustable professional activities for neurocritical care advanced practice providers.

The U.S. HHS announced 15 drugs, including deutetrabenazine, will undergo Medicare Part D price negotiations to lower costs for seniors by 2027.

Neurologists Steven Lewis, MD, and Behrang Saminejad, MD, of Lehigh Valley Health Network, provided commentary on the ways to successfully implement focused ultrasound as a treatment for essential tremor and Parkinson disease.

Amaza Reitmeier and Ashwini Sharan, MD, gave clinical perspectives on the CE Mark approval for Medtronic’s BrainSense Adaptive DBS and Electrode Identifier, 2 technologies geared towards patients with Parkinson disease.

In the first such reported study, transcranial direct stimulation was shown to be superior over sham in improving pain intensity, headache frequency, and neck pain in patients with cervicogenic headaches.

Adjusted models confirmed a consistent negative correlation between serum vitamin D and migraine prevalence, with statistical significance (P < 0.05) across all analyses.

Crossover-treated patients demonstrated clinically meaningful and statistically significant improvements in functional outcomes despite being older at the time of treatment.